Anti-Human CD276/B7-H3 Recombinant Nanobody (SAA2193) (HV612023)

Name: Anti-Human CD276/B7-H3 Recombinant Nanobody (SAA2193)
Brand: abinScience
SKU: HV612023
Price: 126 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

20ug
50ug
100ug
1mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue

HV612023

Description

Anti-Human CD276/B7-H3 Nanobody (SAA2193) [SAA2193] (HV612023) is a alpaca monoclonal antibody detecting B7-H3 in ELISA. Suitable for Human.

Reactivité des espèces

Human

Applications

ELISA

Espèce hôte

Alpaca

Clonalité

Monoclonal

Isotype

VHH-6His

ID de clone

SAA2193

Cible

4Ig-B7-H3, B7 homolog 3, B7-H3, B7H3, CD276, CD276 antigen, Costimulatory molecule

Niveau d'endotoxines

< 10 EU/mg

Pureté

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Numéro d'accès

Q5ZPR3

Forme

Liquid

Tampon de stockage

0.01M PBS pH 7.4.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
ELISA	1:2000-1:20000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Contexte

CD276 antigen (B7-H3) is a ~57 kDa protein. May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. CD276 is the therapeutic target of omburtamab (clinical).

Note

For research use only.

Images